Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 8/20 | 0.52 |
| ▸ | KAT2B | Q92831 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20945081 | 0.80 | KAT2B (0.48) | TNFKAT2BMAPTALDH1A1 | |
| SCHEMBL19172686 | 0.79 | SMN1; SMN2 (0.40) | TNFSMN1; SMN2LMNAPKMMAPT | |
| SCHEMBL6975296 | 0.78 | LMNA (0.49) | TNFSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL19171858 | 0.75 | MITF (0.50) | TNFSMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL16794655 | 0.74 | CYP1A2 (0.46) | SMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL19172697 | 0.74 | NPSR1 (0.46) | SMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL19171859 | 0.73 | AKR1B10 (0.44) | SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL19171319 | 0.72 | GRIN2B (0.38) | SMN1; SMN2 | |
| SCHEMBL14993557 | 0.71 | MAPT (0.51) | SMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL6968546 | 0.69 | ELANE (0.47) | SMN1; SMN2LMNAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415345-B | Pyridazinone-based broad-spectrum anti-influenza inhibitors | 豪夫迈·罗氏有限公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-3478671-B1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-05-13 | — | — | EP | disclosed |
| US-10597380-B2 | Pyridazinone-based broad spectrum anti-influenza inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190127349-A1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127349-A1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | ABCG2, PIR, PRNP | TNF 4528/4885KAT2B 2950/4885SMN1; SMN2 4559/4885 |
| US-10597380-B2 | Pyridazinone-based broad spectrum anti-influenza inhibitors | ABCG2, PIR, PRNP | TNF 4528/4885KAT2B 2950/4885SMN1; SMN2 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.